https://scholars.lib.ntu.edu.tw/handle/123456789/431176
標題: | Statins improve outcomes of nonsurgical curative treatments in hepatocellular carcinoma patients | 作者: | Wu L.-L. Hsieh M.-C. Chow J.-M. SHING-HWA LIU Chang C.-L. Wu S.-Y. |
關鍵字: | Adjuvant therapy; Curative treatment; HCC; PEI; RFA; Statins; Surgery | 公開日期: | 2016 | 出版社: | Lippincott Williams and Wilkins | 卷: | 95 | 期: | 36 | 來源出版物: | Medicine (United States) | 摘要: | Statins are associated with a reduced risk of hepatocellular carcinoma (HCC) and have the potential to be an adjuvant agent for HCC. In this study, we examined whether statin use is associated with additional benefits among patients who received curative treatments (CTs) such as surgery, percutaneous ethanol injection (PEI), and radiofrequency ablation (RFA). We conducted a cohort study using the Taiwan National Health Insurance Research Data linked to the Taiwan Cancer Registry in 2001 to 2012. The patient cohort consisted of those who received different treatments, and we compared patients who received statins with those who did not. Statin users were defined as patients who received >28 cumulative defined daily doses after their HCC diagnosis. We used a time-dependent Cox proportional method to model the time from the HCC diagnosis to any death and HCC death between men who received statins and those who did not after adjusting for confounders. Data on statin prescriptions were collected every 6 months to define the user status. In total, 18,892 patients were included, and the mean follow-up duration was 1.74 years. The adjusted hazard ratio (aHR) of allcause deaths increased in HCC patients who received RFA/PEI compared to those who received surgery (P<0.0001 and P<0.05, with aHRs of 1.81 and 1.16, respectively, for hepatitis B virus [HBV] or non-HBV HCC). However, with the addition of statin use to RFA or PEI, the overall survival was statistically equal. Surgical resection is still superior over other therapies. If HCC patients cannot meet the criteria for surgery, the addition of statin use to RFA or PEI might improve HCC survival. Copyright ? 2016 the Author(s). Published by Wolters Kluwer Health, Inc. All. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84988354894&doi=10.1097%2fMD.0000000000004639&partnerID=40&md5=85130e2be08ad57989241863a86ecdb0 https://scholars.lib.ntu.edu.tw/handle/123456789/431176 |
ISSN: | 0025-7974 | DOI: | 10.1097/MD.0000000000004639 | SDG/關鍵字: | acetylsalicylic acid; hydroxymethylglutaryl coenzyme A reductase inhibitor; interferon; metformin; nucleoside analog; alcohol; hydroxymethylglutaryl coenzyme A reductase inhibitor; solvent; adult; aged; Article; cancer palliative therapy; cancer patient; cancer surgery; cancer survival; cohort analysis; controlled study; death; disease association; female; follow up; hepatitis B; Hepatitis B virus; human; liver cell carcinoma; major clinical study; male; multimodality cancer therapy; outcome assessment; overall survival; percutaneous ethanol injection; priority journal; radiofrequency ablation; Carcinoma, Hepatocellular; catheter ablation; middle aged; treatment outcome; Aged; Carcinoma, Hepatocellular; Catheter Ablation; Cohort Studies; Ethanol; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Solvents; Treatment Outcome |
顯示於: | 毒理學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。